AdvertisementSupported byBusiness BriefingBy ReutersEuropean regulators have started a review into the safety of Gilead Sciencesâ€™ leukemia drug Zydelig over concerns about serious adverse events, including deaths. The review was prompted by an increased rate of harmful events, mostly because of infections, in three clinical trials that tested the drug in combination with other cancer medicines, the European Medicines Agency said on Friday. Zydelig is approved in Europe for treating chronic lymphocytic leukemia in combination with Rituxan, made by Roche, and on its own for treating follicular lymphoma.Advertisement